<SUBMISSION>
<ACCESSION-NUMBER>0001299933-05-001554
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>2
<PERIOD>20050404
<ITEMS>5.02
<FILING-DATE>20050405
<DATE-OF-FILING-DATE-CHANGE>20050404
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>NOVAVAX INC
<CIK>0001000694
<ASSIGNED-SIC>2836
<IRS-NUMBER>222816046
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-26770
<FILM-NUMBER>05731531
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>508 LAPP ROAD
<CITY>MALVERN
<STATE>PA
<ZIP>19355
<PHONE>4849131200
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>508 LAPP ROAD
<CITY>MALVERN
<STATE>PA
<ZIP>19355
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>htm_3962.htm
<DESCRIPTION>LIVE FILING
<TEXT>
<!-- CoverPageHeader start -->
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> Novavax, Inc. (Form: 8-K) </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<P>
<!-- CoverPageHeader end --><!-- CoverPageTitle START -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<HR NOSHADE>
<P>
<P ALIGN="CENTER">
<FONT SIZE="4">
		UNITED STATES<BR>
	SECURITIES AND EXCHANGE COMMISSION
</FONT>
<BR>
<FONT SIZE="2">
	WASHINGTON, D.C. 20549
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="5">
	FORM 8-K
</FONT>
<FONT SIZE="2">

</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="3">
	CURRENT REPORT
</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934
</FONT>
</P>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Date of Report (Date of Earliest Event Reported):
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	April 4, 2005
</FONT>
</TD>
</TR>
</TABLE>
<BR>
</CENTER>
<!-- CoverPageTitle END --><!-- CoverPageRegistrant START -->
<P ALIGN="CENTER"><!-- -->
<FONT SIZE="6">
	Novavax, Inc.
</FONT>
<FONT SIZE="2">
<BR>__________________________________________<BR>
	(Exact name of registrant as specified in its charter)
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="33%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="33%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Delaware
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	0-26770
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	22-2816046
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________________<BR>
	(State or other jurisdiction
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________<BR>
	(Commission
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
______________<BR>
	(I.R.S. Employer
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	of incorporation)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	File Number)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Identification No.)
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	508 Lapp Road, Malvern, Pennsylvania
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	19355
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_________________________________<BR>
	(Address of principal executive offices)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
___________<BR>
	(Zip Code)
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">

<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Registrant&#146;s telephone number, including area code:
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	484-913-1200
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Not Applicable
<BR>______________________________________________<BR>
	Former name or former address, if changed since last report
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="2">
	&nbsp;
</FONT>
<!-- CoverPageRegistrant END --><P><FONT SIZE="2">
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:</FONT>
</P>
<P><FONT SIZE="2">
[&nbsp;&nbsp;]&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<br>
</P></FONT><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
On April 4, 2005, Novavax announced changes to it's Board of Directors and senior management team.  Gary C. Evans, a Director of Novavax since 1998, was elected by the Board of Directors to the position of Chairman of the Board.  Former Chairman, Dr. Denis O'Donnell, will remain on the Board as a Director.  These changes became effective as of April 4, 2005.<br><br>The Board also approved the promotion of Dr. Rahul Singhvi to Senior Vice-President and Chief Operating Officer effective April 4, 2005.<br><br>Rider:  Dr. Singhvi was promoted from his position as Vice President &#x2013; Pharmaceutical Development and Manufacturing, which position he had held since joining the company in April 2004. Prior to joining Novavax, Dr. Singhvi worked for approximately 10 years with Merck & Co., serving as a Director within the Merck Manufacturing division, and held leadership positions that included responsibility for technology transfer and development of new products. Dr. Singhvi will continue to report to the President and Chief Executive Officer of the company.<br><br>A copy of the press release announcing these appointments is attached hereto as Exhibit 99.1 and incorporated herein by reference.<br><br>Item 9.01. Financial Statements and Exhibits<br><br>99.1 Press Release dated April 4, 2005<br>
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><P ALIGN="LEFT" STYLE="FONT-SIZE: 10PT"></P><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- SignatureHeader START -->
<P ALIGN="CENTER">
<FONT SIZE="2">
<B>
	SIGNATURES
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
	Pursuant to the requirements of the Securities Exchange Act of 1934, the
	registrant has duly caused this report to be signed on its behalf by the
	undersigned hereunto duly authorized.
</FONT>
</P>
<!-- SignatureHeader END --><!-- Signature START -->
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="19%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="3%">
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="43%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" VALIGN="TOP" ALIGN="LEFT">
<FONT SIZE="2">
	Novavax, Inc.
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
<I>
	April 4, 2005
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	By:
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Dennis W. Genge
</I>
<BR>
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<HR SIZE="1" NOSHADE>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Name: Dennis W. Genge
</I>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Title: Vice President and Chief Financial Officer
</I>
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<!-- Signature END --><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><P ALIGN="CENTER">
<FONT SIZE="2">
	Exhibit&nbsp;Index
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="60%">
<TR VALIGN="BOTTOM">
<TD WIDTH="8%">
	&nbsp;
</TD>
<TD WIDTH="15%">
	&nbsp;
</TD>
<TD WIDTH="77%">
	&nbsp;
</TD>
</TR>

<BR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Exhibit No.
</B>
</FONT>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Description
</B>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="CENTER">
<HR SIZE="1" NOSHADE>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="CENTER">
<HR ALIGN="LEFT" SIZE="1" WIDTH="88%" NOSHADE>
</TD>
</TR>





<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" WIDTH="8%" nowrap>
<FONT SIZE="2">
<DIV ALIGN="LEFT">
	99.1
</DIV>
</FONT>
</TD>
<TD WIDTH="15%">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
<FONT SIZE="2">
Press Release
</FONT>
</TD>
</TR></TABLE></CENTER><!-- HTMLFooter START -->
</BODY>
</HTML>
<!-- HTMLFooter END -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> EX-99.1 </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><FONT style="font-size: 12pt"><B>FOR IMMEDIATE RELEASE</B></FONT>


<P align="right" style="font-size: 12pt">NASDAQ symbol: NVAX



<P align="center" style="font-size: 12pt"><FONT style="font-size: 11pt"><B>NOVAVAX BOARD OF DIRECTORS ELECTS GARY C. EVANS CHAIRMAN AND PROMOTES RAHUL SINGHVI TO SENIOR<BR>
VICE-PRESIDENT AND CHIEF OPERATING OFFICER</B></FONT>



<P align="left" style="font-size: 11pt"><B><I>MALVERN, PA., April&nbsp;4, 2005 </I></B>&#150; Novavax, Inc. (Nasdaq: NVAX), a specialty biopharmaceutical company,
today announced changes to its Board of Directors and senior management team. Effective today, Gary
C. Evans, a Director of Novavax since 1998, has been elected by the Board of Directors to the
position of Chairman of the Board. Mr.&nbsp;Evans&#146; role as Chairman will be a non-executive position.
Former Chairman Dr.&nbsp;Denis O&#146;Donnell will remain on the Board as a Director.


<P align="left" style="font-size: 11pt">&#147;On behalf of the Board, I would like to thank Dr.&nbsp;O&#146;Donnell for his five years of distinguished
service as Chairman. We continue to recognize the great value of his clinical experience, as well
as, his continued participation on the Board,&#148; said Gary C. Evans, Chairman of the Board of
Novavax, Inc.


<P align="left" style="font-size: 11pt">The Board also approved the promotion of Dr.&nbsp;Rahul Singhvi to Senior Vice-President and Chief
Operating Officer of Novavax, from his prior position as Vice-President Pharmaceutical Development
and Manufacturing Operations. Dr.&nbsp;Singhvi will continue to report to Nelson M. Sims, President and
Chief Executive Officer of Novavax.


<P align="left" style="font-size: 11pt">&#147;I know that I echo the thoughts of the entire Board of Directors of Novavax by saying we believe
the value of our unique drug delivery technology developed by our scientists over the past ten
years along with the significant capital investment from our shareholders, has yet to be realized
by the marketplace. We have developed a product utilizing this new technology,
ESTRASORB</FONT><FONT style="font-size: 10pt"><sup>&#174;</sup>, </FONT><FONT style="font-size: 11pt">that has been approved by the FDA, and is gaining acceptance by
the consumer, although at a pace below our original expectations. Novavax has a very dedicated work
force that has the drive to accomplish our goals and objectives,&#148; said Gary C. Evans, Chairman of
Novavax. &#147;My immediate priority will be to ensure the business fundamentals of corporate governance
and accountability are administered, and provide leadership and strategic direction to support the
existing framework. I will attempt to use my financial background and experience to assist the
management team in regaining our financial footing in an effort to ensure our future viability.&#148;</FONT>


<P align="left" style="font-size: 11pt">Mr.&nbsp;Evans retired today as President and Chief Executive Officer of Magnum Hunter Resources, an
independent natural gas and oil exploration and development company, which he originally founded in
1985. The Company is based in Irving, Texas and traded on the New York Stock Exchange. Magnum
Hunter is in the process of merging with Cimarex Energy in a $2.1&nbsp;billion transaction with closing
anticipated prior to June&nbsp;30, 2005. Mr.&nbsp;Evans will remain as a Board member of Magnum Hunter. Mr.
Evans has served in the senior leadership position as well as Chairman of all the Magnum Hunter
subsidiaries since their formation or acquisition dating back to 1985. Mr.&nbsp;Evans also serves on the
Board of Advisors of the Maguire Energy Institute at Southern Methodist University. Mr.&nbsp;Evans was
recognized by Ernst and Young as the Southwest Area 2004 Entrepreneur of the Year for the Energy
Sector and was recently inducted into the World Hall of Fame for Ernst &#038; Young Entrepreneurs.


<P align="left" style="font-size: 11pt">Since Dr.&nbsp;Singhvi joined Novavax one year ago, his leadership and knowledge in manufacturing and
pharmaceutical development have been critical to Novavax achieving a streamlined ESTRASORB
production process enabling the product launch, completing the installation of new high speed
packaging equipment, achieving an agreement with Ranbaxy Laboratories to evaluate a new transdermal
product, and advancing new MNP candidates into pre-clinical trials. Dr.&nbsp;Singhvi holds a Master and
Doctorate of Science degrees in Chemical Engineering from the Massachusetts Institute of Technology
and a Master of Business Administration from the Wharton School. Dr.&nbsp;Singhvi joined Novavax after
10&nbsp;years experience with Merck &#038; Co. Dr.&nbsp;Singhvi served as a Director within the Merck
Manufacturing division, and held leadership positions that included responsibility for technology
transfer and development of new products. He holds several patents in the area of cell culturing
systems and has co-authored numerous publications and abstracts on biochemical engineering and cell
physiology.


<P align="left" style="font-size: 11pt"><B>Corporate Governance</B>
<BR>
The Board of Directors also approved several other corporate governance changes. The Company
announced its plans to strengthen the capabilities of its Board of Directors by initiating a search
for two new board members with a preference given to pharmaceutical product development experience
and with general management experience in the health-care or life-science sector. The Board also
established a term limit and an age limit for Directors. Under the new governance structure, unless
the Board determines that an independent Director is strategically critical to the Company at the
date of re-election, a Director shall not be re-elected beyond ten years of service or the age of
75.


<P align="left" style="font-size: 11pt"><B>About Novavax Inc.</B>
<BR>
Novavax, Inc. is a specialty biopharmaceutical company engaged in the research, development and
commercialization of proprietary products focused on drug delivery and vaccine development. Novavax
sells, markets, and distributes a line of women&#146;s health prescription pharmaceuticals through its
specialty sales force calling on obstetricians and gynecologists throughout the United States
including ESTRASORB, its topical emulsion for estrogen therapy. Novavax&#146;s micellar nanoparticle
technology involves the use of patented oil and water nanoemulsions that it believes can be used as
vehicles for the topical delivery of a wide variety of drugs and other therapeutic products,
including hormones. In addition, Novavax conducts research and development on preventative and
therapeutic vaccines and proteins for a variety of infectious diseases, including HIV, influenza,
SARS and E-selectin tolerogen for the prevention of stroke.


<P align="left" style="font-size: 11pt"><FONT style="font-size: 9pt">Statements made in this press release that state Novavax&#146;s or management&#146;s intentions, hopes,
beliefs, expectations, or predictions of the future are forward-looking statements. Forward-looking
statements include but are not limited to statements regarding product sales, future product
development and related clinical trials and statements regarding future research and development.
Novavax&#146;s actual results could differ materially from those projected in such forward-looking
statements. Factors that could cause actual results to differ materially from those in the
forward-looking statements include, among other things, the following: general economic and
business conditions; competition; unexpected changes in technologies and technological advances;
ability to commercialize and manufacture products; results of clinical studies; research and
development activities; changes in, or failure to comply with, governmental regulations; and the
ability to obtain adequate financing in the future. Additional information is contained in
Novavax&#146;s annual report on Form&nbsp;10K for the year ended December&nbsp;31, 2004. incorporated herein by
reference. Statements made herein should be read in conjunction with Novavax&#146;s Form&nbsp;10K. Copies of
the filing may be obtained by contacting Novavax at 508 Lapp Road, Malvern, PA 19355 Tel
484-913-1200 or the SEC at <U>www.sec.gov</U>.</FONT>


<P align="left" style="font-size: 9pt"><FONT style="font-size: 11pt">For further information:
</FONT><BR>
<FONT style="font-size: 10pt">INVESTOR RELATIONS
<BR>
Nelson M. Sims, President and CEO
<BR>
Rita Freedman, Manager Investor Relations
<BR>
Novavax Inc.
<BR>
Tel: (484)&nbsp;913-1200
<BR>
Email: rfreedman@novavax.com</FONT>



<P align="center" style="font-size: 10pt; display: none">


</BODY>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SUBMISSION>
